NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
The National Comprehensive Cancer Network (NCCN) updated its Bladder Cancer guidelines to include Natera's Signatera with a Category 1 recommendation for adjuvant treatment in muscle-invasive bladder cancer. This marks the third NCCN guideline inclusion for Signatera, supported by Phase 3 evidence from the IMvigor011 trial, and validates the test as a prognostic and predictive biomarker.
Key figures
- Trial name
- IMvigor011
- Trial phase
- Phase 3
- Guideline designation
- Category 1
- Nccn recommendation count
- 3
- Peer reviewed publications
- 400+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.